Meet us at #ATW26 in San Diego, February 9-12.
Our Team
Our Services
CMC
Regulatory
Nonclinical
Clinical
Quality & Compliance
Supply Chain
Commercial Launch
Business Analytics
View all Services
Our Advantage
More
Our Global Offices
General Inquiries
Careers/RbD
Our Values
Conference Schedule
Press Room
Regulatory Roundup
DHCG Webinars
Print Library
Testimonials
Annual Lookback (Latest)
Annual Lookback (Back Issues)
Quarter Horse Archive
QMS in a Box
Privacy Policy
Terms of Service
Ready to accelerate your program?
Request Consultation
Contact Us
Case Study Library
Request Consultation
Back to resources
Thought Leadership Expertise
Press Room
Choose a category…
Straight From the Horse’s Mouth
White Papers
Publications
Choose a tag…
3PL
Best Practices
Cell & Gene Therapy
Clinical
Clinical Operations
Clinical Supply Chain Management
CMC
Commercial
Commercial Launch
Commercial Supply Chain Launch Readiness
Commercial Systems
Demand & Operations Planning
Finance
General
Global Trade Compliance
Info Sheets
IT
Logistics
Manufacturing
Mature
Medical Affairs
Operational Excellence
Perspective
Press Room
Preclinical
Publications
Quality
Serialization
Supply Chain
Supply Chain Planning & Digitization
Supply Planning
Supply Risk Management
Uncategorized
White Papers
Arcline Investment Management And Dark Horse Consulting Group Enter Into Strategic Partnership
Amanda Mack and Alicja Fiedorowicz on FDA's Draft Guidance on Safety Testing of Human Allogeneic Cells
Anthony Davies considers the possibility of a new CMC norm in this BPI article
"FDA's CBER Issues Final Guidance For CAR-T Cell Products" by Anne Lamontagne and Wendy Liang
"The sweet cell of success," by DHC's Blackford and Manley
2017: The Dawning of Cell and Gene Therapies
Product approvals and a regulatory focus on regenerative medicines have made 2017 a breakthrough year for cell and gene therapies, say consultants.
Previous
